Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

  • Discontinued
  • GID-TAG398

Documents

Documents created during the development process.

Renal cell carcinoma (second line metastatic) - pazopanib: draft scope for consultation

Renal cell carcinoma (second line metastatic) - pazopanib: provisional matrix for consultation